The DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.
Biomarker of Neuroinflammation in Parkinson’s Disease
Open accessAbstract
Parkinson’s disease (PD) is caused by abnormal accumulation of α-synuclein in dopaminergic neurons of the substantia nigra, which subsequently causes motor symptoms. Neuroinflammation plays a vital role in the pathogenesis of neurodegeneration in PD. This neuroinflammatory neurodegeneration involves the activation of microglia, upregulation of proinflammatory factors, and gut microbiota. In this review, we summarized the recent findings on detection of PD by using inflammatory biomarkers, such as interleukin (IL)-1β, IL-2, IL-6, IL-10, tumor necrosis factor (TNF)-α; regulated upon activation, normal T cell expressed and presumably secreted (RANTES) and high-sensitivity c-reactive protein (hsCRP); and radiotracers such as [11C]PK11195 and [18F]-FEPPA, as well as by monitoring disease progression and the treatment response. Many PD-causing mutations in SNCA, LRRK2, PRKN, PINK1, and DJ-1 are also associated with neuroinflammation. Several anti-inflammatory medications, including nonsteroidal anti-inflammatory drugs (NSAID), inhibitors of TNF-α and NLR family pyrin domain containing 3 (NLRP3), agonists of nuclear factor erythroid 2-related factor 2 (NRF2), peroxisome proliferator-activated receptor gamma (PPAR-γ), and steroids, have demonstrated neuroprotective effects in in vivo or in vitro PD models. Clinical trials applying objective biomarkers are required to investigate the therapeutic potential of anti-inflammatory medications for PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Teema, A. M., Zaitone, S. A., & Moustafa, Y. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.034 · Cited by 66
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 3×
“Numerous autoantibodies target CNS-specific proteins, such as tau, S100B, glial fibrillar acidic protein (GFAP) [33–35], neurofilament [36,37], GM1 [38], and neuronal calcium channels [39]; moreover, autoantibodies to α-synuclein [40,41] have also been discovered.”
BackgroundA role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Nakahira, K., Haspel, J. A., Rathinam, V. A. K., Lee, S.-J., Dolinay, T., Lam, H. C., Englert, J. A., Rabinovitch, M., Cernadas, M., Kim, H. P., et al. (2011) · Nature Immunology · doi:10.1038/ni.1980 · Cited by 3,049
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin
Narendra, D. P., Jin, S. M., Tanaka, A., Suen, D.-F., Gautier, C. A., Shen, J., Cookson, M. R., & Youle, R. J. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000298 · Cited by 2,944
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Mitochondrial DNA stress primes the antiviral innate immune response
West, A. P., Khoury-Hanold, W., Staron, M., Tal, M. C., Pineda, C. M., Lang, S. M., Bestwick, M., Duguay, B. A., Raimundo, N., MacDuff, D. A., et al. (2015) · Nature · doi:10.1038/nature14156 · Cited by 1,975
Moore, K. (1993) · Annual Review of Immunology · doi:10.1146/annurev.immunol.11.1.165 · Cited by 1,884
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,825
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene
Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A. C., & Horak, I. (1993) · Cell · doi:10.1016/0092-8674(93)80067-o · Cited by 1,744
The role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657
Papadopoulos, V., Baraldi, M., Guilarte, T. R., Knudsen, T. B., Lacapère, J.-J., Lindemann, P., Norenberg, M. D., Nutt, D., Weizman, A., Zhang, M.-R., et al. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.06.005 · Cited by 1,389
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 1×
“A well-known example is [11C](R)PK11195 binding to several brain regions in patients with PD [7].”
BackgroundGoedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Unger, M. M., Spiegel, J., Dillmann, K.-U., Grundmann, D., Philippeit, H., Bürmann, J., Faßbender, K., Schwiertz, A., & Schäfer, K.-H. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.08.019 · Cited by 1,159
Interleukin-6, a Major Cytokine in the Central Nervous System
Erta, M., Quintana, A., & Hidalgo, J. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4679 · Cited by 1,087
Malek, T. R. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090357 · Cited by 1,079
Tumor necrosis factor: a pleiotropic cytokine and therapuetic target
Tracey, M. D., & Cerami, P. D. (1994) · Annual Review of Medicine · doi:10.1146/annurev.med.45.1.491 · Cited by 1,063
New insights into the regulation of T cells by γc family cytokines
Rochman, Y., Spolski, R., & Leonard, W. J. (2009) · Nature Reviews Immunology · doi:10.1038/nri2580 · Cited by 1,053
Genomewide Association Study of Leprosy
Zhang, F.-R., Huang, W., Chen, S.-M., Sun, L.-D., Liu, H., Li, Y., Cui, Y., Yan, X.-X., Yang, H.-T., Yang, R.-D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903753 · Cited by 1,031
Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90746-3 · Cited by 986
Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production
White, M. J., McArthur, K., Metcalf, D., Lane, R. M., Cambier, J. C., Herold, M. J., van Delft, M. F., Bedoui, S., Lessene, G., Ritchie, M. E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.036 · Cited by 983
Zhang, Y., Gao, J., Chung, K. K. K., Huang, H., Dawson, V. L., & Dawson, T. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.240347797 · Cited by 982
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
Gordon, R., Albornoz, E. A., Christie, D. C., Langley, M. R., Kumar, V., Mantovani, S., Robertson, A. A. B., Butler, M. S., Rowe, D. B., O’Neill, L. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4066 · Cited by 897
Kim, C., Ho, D.-H., Suk, J.-E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2534 · Cited by 856 · cited 1×
“Knockout of TLR2 reduces the uptake of α-synuclein in mouse microglia [26].”
BackgroundMogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90508-8 · Cited by 855
Apoptotic Caspases Prevent the Induction of Type I Interferons by Mitochondrial DNA
Rongvaux, A., Jackson, R., Harman, C. C. D., Li, T., West, A. P., de Zoete, M. R., Wu, Y., Yordy, B., Lakhani, S. A., Kuan, C.-Y., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.037 · Cited by 847
Microglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 843
Blum-Degena, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., & Riederer, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12192-7 · Cited by 801
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791 · cited 1×
“They also express major histocompatibility complex (MHC) class II, and are associated with damaged neurons in patients with PD [17].”
BackgroundPeroxisome proliferator-activated receptors in inflammation control
Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690453 · Cited by 755
Drosophila Parkin requires PINK1 for mitochondrial translocation and ubiquitinates Mitofusin
Ziviani, E., Tao, R. N., & Whitworth, A. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913485107 · Cited by 735
Glial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701
Toll‐like receptor 4 is required for α‐synuclein dependent activation of microglia and astroglia
Fellner, L., Irschick, R., Schanda, K., Reindl, M., Klimaschewski, L., Poewe, W., Wenning, G. K., & Stefanova, N. (2013) · Glia · doi:10.1002/glia.22437 · Cited by 697
RANTES: a versatile and controversial chemokine
Appay, V., & Rowland-Jones, S. L. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(00)01812-3 · Cited by 650
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration
Choi, I., Zhang, Y., Seegobin, S. P., Pruvost, M., Wang, Q., Purtell, K., Zhang, B., & Yue, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-15119-w · Cited by 608
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease
Boka, G., Anglade, P., Wallach, D., Javoy-Agid, F., Agid, Y., & Hirsch, E. C. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90684-x · Cited by 590
Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation · doi:10.1161/01.cir.0000131519.15067.1f · Cited by 578
Qin, X.-Y., Zhang, S.-P., Cao, C., Loh, Y. P., & Cheng, Y. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2742 · Cited by 554
Peripheral cytokines profile in parkinson’s disease
Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M., & Onofrj, M. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.07.003 · Cited by 547
Mogi, M., Harada, M., Narabayashi, H., Inagaki, H., Minami, M., & Nagatsu, T. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12706-3 · Cited by 545
Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142164 · Cited by 523
Changes in cytokines and neurotrophins in Parkinson’s disease
Nagatsu, T., Mogi, M., Ichinose, H., & Togari, A. (2000) · Advances in Research on Neurodegeneration · doi:10.1007/978-3-7091-6301-6_19 · Cited by 510
Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease
Lin, C.-H., Chen, C.-C., Chiang, H.-L., Liou, J.-M., Chang, C.-M., Lu, T.-P., Chuang, E. Y., Tai, Y.-C., Cheng, C., Lin, H.-Y., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1528-y · Cited by 469
Self-citationAdvances in the genetics of Parkinson disease
Trinh, J., & Farrer, M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.132 · Cited by 466
LRRK2 Inhibition Attenuates Microglial Inflammatory Responses
Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., Cowell, R. M., & West, A. B. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5601-11.2012 · Cited by 463
Visualising microglial activation in vivo
Banati, R. B. (2002) · Glia · doi:10.1002/glia.10144 · Cited by 428
Reynolds, A. D., Stone, D. K., Hutter, J. A. L., Benner, E. J., Mosley, R. L., & Gendelman, H. E. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901852 · Cited by 406
Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice
Challis, C., Hori, A., Sampson, T. R., Yoo, B. B., Challis, R. C., Hamilton, A. M., Mazmanian, S. K., Volpicelli-Daley, L. A., & Gradinaru, V. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0589-7 · Cited by 405
Physiological and pathological roles of interleukin-6 in the central nervous system
Gruol, D. L., & Nelson, T. E. (1997) · Molecular Neurobiology · doi:10.1007/bf02740665 · Cited by 404
Parkinson's disease: Autoimmunity and neuroinflammation
De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M. I., Gallo, A., Conte, M., Rosato, C., Ciniglio Appiani, M., & de Vincentiis, M. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.022 · Cited by 389
Peter, I., Dubinsky, M., Bressman, S., Park, A., Lu, C., Chen, N., & Wang, A. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0605 · Cited by 386 · cited 2×
“A cohort study reported that early exposure to anti-TNF therapy is associated with reduced PD incidence [160].”
BackgroundDehmer, T., Heneka, M. T., Sastre, M., Dichgans, J., & Schulz, J. B. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02210.x · Cited by 382
Breidert, T., Callebert, J., Heneka, M. T., Landreth, G., Launay, J. M., & Hirsch, E. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00990.x · Cited by 373
Theodore, S., Cao, S., McLean, P. J., & Standaert, D. G. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818e5e99 · Cited by 367
MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration
Cebrián, C., Zucca, F. A., Mauri, P., Steinbeck, J. A., Studer, L., Scherzer, C. R., Kanter, E., Budhu, S., Mandelbaum, J., Vonsattel, J. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms4633 · Cited by 338
Microglia-Mediated Inflammation and Neurodegenerative Disease
Xu, L., He, D., & Bai, Y. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9593-4 · Cited by 332
Association of circulating TNF-α and IL-6 with ageing and parkinsonism
Dobbs, R. J., Charlett, A., Purkiss, A. G., Dobbs, S. M., Weller, C., & Peterson, D. W. (1999) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1999.tb00721.x · Cited by 324
Brodacki, B., Staszewski, J., Toczyłowska, B., Kozłowska, E., Drela, N., Chalimoniuk, M., & Stępien, A. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.06.040 · Cited by 316
Cytokines in Parkinson’s disease
Nagatsu, T., Mogi, M., Ichinose, H., & Togari, A. (2000) · Advances in Research on Neurodegeneration · doi:10.1007/978-3-7091-6284-2_12 · Cited by 308
Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE‐PD)
Williams‐Gray, C. H., Wijeyekoon, R., Yarnall, A. J., Lawson, R. A., Breen, D. P., Evans, J. R., Cummins, G. A., Duncan, G. W., Khoo, T. K., Burn, D. J., et al. (2016) · Movement Disorders · doi:10.1002/mds.26563 · Cited by 304
The potential biological and clinical significance of the soluble tumor necrosis factor receptors
Aderka, D. (1996) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(96)00026-3 · Cited by 285
A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity
Stolzenberg, E., Berry, D., Yang, D., Lee, E. Y., Kroemer, A., Kaufman, S., Wong, G. C. L., Oppenheim, J. J., Sen, S., Fishbein, T., et al. (2017) · Journal of Innate Immunity · doi:10.1159/000477990 · Cited by 284
Pathogenic role of glial cells in Parkinson's disease
Teismann, P., Tieu, K., Cohen, O., Choi, D., Wu, D. C., Marks, D., Vila, M., Jackson‐Lewis, V., & Przedborski, S. (2003) · Movement Disorders · doi:10.1002/mds.10332 · Cited by 275
Lastres-Becker, I., García-Yagüe, A. J., Scannevin, R. H., Casarejos, M. J., Kügler, S., Rábano, A., & Cuadrado, A. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6549 · Cited by 274
Lee, E.-J., Woo, M.-S., Moon, P.-G., Baek, M.-C., Choi, I.-Y., Kim, W.-K., Junn, E., & Kim, H.-S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903480 · Cited by 267
Parkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration
Frank-Cannon, T. C., Tran, T., Ruhn, K. A., Martinez, T. N., Hong, J., Marvin, M., Hartley, M., Treviño, I., O'Brien, D. E., Casey, B., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3001-08.2008 · Cited by 261
Sanchez-Guajardo, V., Febbraro, F., Kirik, D., & Romero-Ramos, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008784 · Cited by 256
Fyn kinase regulates misfolded α-synuclein uptake and NLRP3 inflammasome activation in microglia
Panicker, N., Sarkar, S., Harischandra, D. S., Neal, M., Kam, T.-I., Jin, H., Saminathan, H., Langley, M., Charli, A., Samidurai, M., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182191 · Cited by 254
Nitrated alpha‐synuclein‐activated microglial profiling for Parkinson’s disease
Reynolds, A. D., Glanzer, J. G., Kadiu, I., Ricardo‐Dukelow, M., Chaudhuri, A., Ciborowski, P., Cerny, R., Gelman, B., Thomas, M. P., Mosley, R. L., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05087.x · Cited by 244
Castaño, A., Herrera, A. J., Cano, J., & Machado, A. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00799.x · Cited by 238
Dursun, E., Gezen-Ak, D., Hanağası, H., Bilgiç, B., Lohmann, E., Ertan, S., Atasoy, İ. L., Alaylıoğlu, M., Araz, Ö. S., Önal, B., et al. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.04.014 · Cited by 237
CSF biomarkers and clinical progression of Parkinson disease
Hall, S., Surova, Y., Öhrfelt, A., Zetterberg, H., Lindqvist, D., & Hansson, O. (2015) · Neurology · doi:10.1212/wnl.0000000000001098 · Cited by 236
Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047387 · Cited by 236
Ferrari, C. C., Pott Godoy, M. C., Tarelli, R., Chertoff, M., Depino, A. M., & Pitossi, F. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.013 · Cited by 235
Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease
Li, Y., Xia, Y., Yin, S., Wan, F., Hu, J., Kou, L., Sun, Y., Wu, J., Zhou, Q., Huang, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719807 · Cited by 230
Gillardon, F., Schmid, R., & Draheim, H. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.02.001 · Cited by 222
Eusebi, P., Giannandrea, D., Biscetti, L., Abraha, I., Chiasserini, D., Orso, M., Calabresi, P., & Parnetti, L. (2017) · Movement Disorders · doi:10.1002/mds.27110 · Cited by 220
Daher, J. P. L., Abdelmotilib, H. A., Hu, X., Volpicelli-Daley, L. A., Moehle, M. S., Fraser, K. B., Needle, E., Chen, Y., Steyn, S. J., Galatsis, P., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.660001 · Cited by 210
Cerebrospinal fluid biomarkers in Parkinson disease
Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., & Calabresi, P. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.10 · Cited by 209
Gao, L., Tang, H., Nie, K., Wang, L., Zhao, J., Gan, R., Huang, J., Zhu, R., Feng, S., Duan, Z., et al. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2014.961454 · Cited by 203
PPAR‐gamma‐mediated neuroprotection in a chronic mouse model of Parkinson’s disease
Schintu, N., Frau, L., Ibba, M., Caboni, P., Garau, A., Carboni, E., & Carta, A. R. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06657.x · Cited by 200
Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease
Houser, M. C., Chang, J., Factor, S. A., Molho, E. S., Zabetian, C. P., Hill‐Burns, E. M., Payami, H., Hertzberg, V. S., & Tansey, M. G. (2018) · Movement Disorders · doi:10.1002/mds.27326 · Cited by 199
The role of α-synuclein in neurodegenerative diseases
Bennett, M. C. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.010 · Cited by 197
Müller, T., Blum-Degen, D., Przuntek, H., & Kuhn, W. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb01736.x · Cited by 195
Akundi, R. S., Huang, Z., Eason, J., Pandya, J. D., Zhi, L., Cass, W. A., Sullivan, P. G., & Büeler, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016038 · Cited by 187
Swanson, C. R., Joers, V., Bondarenko, V., Brunner, K., Simmons, H. A., Ziegler, T. E., Kemnitz, J. W., Johnson, J. A., & Emborg, M. E. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-91 · Cited by 186
Ferger, B., Leng, A., Mura, A., Hengerer, B., & Feldon, J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02399.x · Cited by 186
Autoantibodies to alpha‐synuclein in inherited Parkinson’s disease
Papachroni, K. K., Ninkina, N., Papapanagiotou, A., Hadjigeorgiou, G. M., Xiromerisiou, G., Papadimitriou, A., Kalofoutis, A., & Buchman, V. L. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04365.x · Cited by 185
The Role of Inflammatory Cytokines in Cognition and Other Non-Motor Symptoms of Parkinson’s Disease
Menza, M., DeFronzo Dobkin, R., Marin, H., Mark, M. H., Gara, M., Bienfait, K., Dicke, A., & Kusnekov, A. (2010) · Psychosomatics · doi:10.1016/s0033-3182(10)70739-8 · Cited by 180
Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation
Kuai, X.-Y., Yao, X.-H., Xu, L.-J., Zhou, Y.-Q., Zhang, L.-P., Liu, Y., Pei, S.-F., & Zhou, C.-L. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01589-0 · Cited by 179
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
Parnetti, L., Farotti, L., Eusebi, P., Chiasserini, D., De Carlo, C., Giannandrea, D., Salvadori, N., Lisetti, V., Tambasco, N., Rossi, A., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00053 · Cited by 176
Scalzo, P., Kümmer, A., Cardoso, F., & Teixeira, A. L. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2009.10.062 · Cited by 175
Yanamandra, K., Gruden, M. A., Casaite, V., Meskys, R., Forsgren, L., & Morozova-Roche, L. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018513 · Cited by 171
Cookson, M. R. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009415 · Cited by 170
The association between infectious burden and Parkinson's disease: A case-control study
Bu, X.-L., Wang, X., Xiang, Y., Shen, L.-L., Wang, Q.-H., Liu, Y.-H., Jiao, S.-S., Wang, Y.-R., Cao, H.-Y., Yi, X., et al. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.05.015 · Cited by 169
Inflammatory cytokines and NT-proCNP in Parkinson’s disease patients
Koziorowski, D., Tomasiuk, R., Szlufik, S., & Friedman, A. (2012) · Cytokine · doi:10.1016/j.cyto.2012.07.030 · Cited by 165
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
Mollenhauer, B., Caspell‐Garcia, C., Coffey, C. S., Taylor, P., Shaw, L. M. J., Trojanowski, J. Q., Singleton, A. B., Frasier, M. A., Marek, K., Galasko, D. R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004609 · Cited by 165
Ezcurra, A. L. D. L., Chertoff, M., Ferrari, C. C., Graciarena, M., & Pitossi, F. J. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.018 · Cited by 164
Akıl, E., Bulut, A., Kaplan, İ., Özdemir, H. H., Arslan, D., & Aluçlu, M. U. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1976-1 · Cited by 163
LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same
Berwick, D. C., Heaton, G. R., Azeggagh, S., & Harvey, K. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0344-2 · Cited by 162
Esteras, N., Dinkova-Kostova, A. T., & Abramov, A. Y. (2016) · Biological Chemistry · doi:10.1515/hsz-2015-0295 · Cited by 160
PPAR: a therapeutic target in Parkinson’s disease
Chaturvedi, R. K., & Beal, M. F. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05388.x · Cited by 159
Couch, Y., Alvarez-Erviti, L., Sibson, N. R., Wood, M. J., & Anthony, D. C. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-166 · Cited by 155
Domingo, A., & Klein, C. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63233-3.00014-2 · Cited by 152
Campolo, M., Casili, G., Biundo, F., Crupi, R., Cordaro, M., Cuzzocrea, S., & Esposito, E. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6800 · Cited by 151
Non-Steroidal Anti-Inflammatory Drugs and Brain Inflammation: Effects on Microglial Functions
Ajmone‐Cat, M. A., Bernardo, A., Greco, A., & Minghetti, L. (2010) · Pharmaceuticals · doi:10.3390/ph3061949 · Cited by 144
Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro
Casper, D., Yaparpalvi, U., Rempel, N., & Werner, P. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01294-5 · Cited by 138
Rees, K., Stowe, R. L., Patel, S., Ives, N. J., Breen, K. C., Clarke, C. E., & Ben‐Shlomo, Y. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008454.pub2 · Cited by 136
Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone
Frau, R., Miczán, V., Traccis, F., Aroni, S., Pongor, C., Saba, P., Serra, V., Sagheddu, C., Fanni, S., Congiu, M., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0512-2 · Cited by 136
Misfolded α-synuclein and toll-like receptors: therapeutic targets for Parkinson's disease
Béraud, D., & Maguire‐Zeiss, K. A. (2011) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70008-6 · Cited by 135
Stypuła, G., Radek, M., Stepien, H., Żylińska, K., & Pawlikowski, M. (1996) · NeuroImmunoModulation · doi:10.1159/000097237 · Cited by 134
Umeno, J., Asano, K., Matsushita, T., Matsumoto, T., Kiyohara, Y., Iida, M., Nakamura, Y., Kamatani, N., & Kubo, M. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21651 · Cited by 131
Scalzo, P. L., Kümmer, A., Cardoso, F., & Teixeira, A. L. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.08.001 · Cited by 126
Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients
Rota, E., Bellone, G., Rocca, P., Bergamasco, B., Emanuelli, G., & Ferrero, P. (2006) · Neurological Sciences · doi:10.1007/s10072-006-0562-6 · Cited by 125
Circulating interleukin-15 and RANTES chemokine in Parkinson’s disease
Rentzos, M., Nikolaou, C., Andreadou, E., Paraskevas, G. P., Rombos, A., Zoga, M., Tsoutsou, A., Boufidou, F., Kapaki, E., & Vassilopoulos, D. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00894.x · Cited by 123
Lipopolysaccharide and Tumor Necrosis Factor Regulate Parkin Expression via Nuclear Factor-Kappa B
Tran, T. A. T., Nguyen, A. D., Chang, J., Goldberg, M. S., Lee, J., & Tansey, M. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023660 · Cited by 121
Trudler, D., Weinreb, O., Mandel, S. A., Youdim, M. B. H., & Frenkel, D. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12633 · Cited by 121
Genetic Forms of Parkinson's Disease
Kim, C., & Alcalay, R. N. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1601567 · Cited by 120
Feany, M. Β., & Pallanck, L. J. (2003) · Neuron · doi:10.1016/s0896-6273(03)00201-0 · Cited by 115
Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression
Алексеевна, Г. М., Sewell, R. D. E., Yanamandra, K., Davidova, T. V., Kucheryanu, V. G., Bocharov, E. V., Bocharova, O. A., Polyschuk, V. V., Sherstnev, V. V., & Morozova‐Roche, L. A. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.12.001 · Cited by 115
Circulating interleukin-10 and interleukin-12 in Parkinson’s disease
Rentzos, M., Nikolaou, C., Andreadou, E., Paraskevas, G. P., Rombos, A., Zoga, M., Tsoutsou, A., Boufidou, F., Kapaki, E., & Vassilopoulos, D. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01103.x · Cited by 114
Parkinson disease with REM sleep behavior disorder: Features, α-synuclein, and inflammation
Hu, Y., Yu, S., Zuo, L.-J., Cao, C.-J., Wang, F., Chen, Z.-J., Du, Y., Lian, T., Wang, Y., Chan, P., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001308 · Cited by 112
Poly, T. N., Islam, M. M., Yang, H., & Li, Y.-C. J. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2561-y · Cited by 108
Kim, K. S., Kim, J.-S., Park, J. Y., Suh, Y. H., Jou, I., Joe, E.-H., & Park, S. M. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt332 · Cited by 107
Sairam, K., Saravanan, K. S., Banerjee, R., & Mohanakumar, K. P. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04174-4 · Cited by 106
Hassanzadeh, K., & Rahimmi, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26865 · Cited by 106
Autoantibodies in Neurodegenerative Diseases: Antigen-Specific Frequencies and Intrathecal Analysis
Terryberry, J. W., Thor, G. T., & Peter, J. B. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00049-9 · Cited by 104
Imaging Striatal Microglial Activation in Patients with Parkinson’s Disease
Koshimori, Y., Ko, J.-H., Mizrahi, R., Rusjan, P., Mabrouk, R., Jacobs, M. F., Christopher, L., Hamani, C., Lang, A. E., Wilson, A. A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138721 · Cited by 100
Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain
Mogi, M., Harada, M., Kondo, T., Riederer, P. F., & Nagatsu, T. (1996) · Journal of Neural Transmission · doi:10.1007/bf01291792 · Cited by 99
Interleukin-6 Serum Levels in Patients with Parkinson’s Disease
Hofmann, K. W., Schuh, A. F. S., Saute, J., Townsend, R., Fricke, D., Leke, R., Souza, D. O., Portela, L. V., Chaves, M. L. F., & Rieder, C. R. M. (2009) · Neurochemical Research · doi:10.1007/s11064-009-9921-z · Cited by 98
Correlation between Serum RANTES Levels and the Severity of Parkinson’s Disease
Tang, P., Li, C., Li, X., Liu, Y., Liu, P., Hou, C., & Li, R. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/208408 · Cited by 96
α1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease
Pirttilä, T., Mehta, P. D., Frey, H., & Wísniewski, H. M. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90026-4 · Cited by 94
Dufek, M., Rektorová, I., Thon, V., Lokaj, J., & Rektor, I. (2015) · Parkinson s Disease · doi:10.1155/2015/898192 · Cited by 87
Maharaj, D. S., Saravanan, K. S., Maharaj, H., Mohanakumar, K. P., & Daya, S. (2003) · Neurochemistry International · doi:10.1016/s0197-0186(03)00170-0 · Cited by 86
Anti-melanin antibodies are increased in sera in Parkinson's disease
Double, K. L., Rowe, D. B., Carew‐Jones, F., Hayes, M., Chan, D. K. Y., Blackie, J., Corbett, A. J., Joffe, R., Fung, V. S. C., Morris, J. G., et al. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.002 · Cited by 85
Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice
Kurkowska‐Jastrzębska, I., Babiuch, M., Joniec‐Maciejak, I., Przybyłkowski, A. M., Członkowski, A., & Członkowska, A. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00078-4 · Cited by 80
PINK1 Deficiency Enhances Inflammatory Cytokine Release from Acutely Prepared Brain Slices
Kim, J., Byun, J.-W., Choi, I., Kim, B., Jeong, H., Jou, I., & Joe, E.-H. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.1.38 · Cited by 78
Reduced alpha‐synuclein in cerebrospinal fluid in synucleinopathies: Evidence from a meta‐analysis
Sako, W., Murakami, N., Izumi, Y., & Kaji, R. (2014) · Movement Disorders · doi:10.1002/mds.26036 · Cited by 77
Positron emission tomography neuroimaging in Parkinson's disease.
Loane, C., & Politis, M. (2011) · PubMed · Cited by 75
Rocha, N. P., Teixeira, A. L., Scalzo, P. L., Barbosa, I. G., de Sousa, M. S., Morato, I. B., Vieira, É. L. M., Christo, P. P., Palotás, A., & Reis, H. J. (2013) · Movement Disorders · doi:10.1002/mds.25752 · Cited by 67
Anti-GM1 ganglioside antibodies in Parkinson's disease
Zappia, M., Crescibene, L., Bosco, D., et al. (2002) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2002.01240.x · Cited by 65
Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson’s disease
Andican, G., Konukoğlu, D., Bozluolçay, M., Bayülkem, K., Firtiına, S., & Burçak, G. (2012) · Acta Neurologica Belgica · doi:10.1007/s13760-012-0015-3 · Cited by 63
Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF ‐α Pathway
Lin, C., Lin, H., Ho, E., Ke, Y., Cheng, M., Shiue, C., Wu, C., Liao, P., Hsu, A. Y., Chu, L., et al. (2021) · Movement Disorders · doi:10.1002/mds.28890 · Cited by 60
Non-Steroidal Anti-Inflammatory Drug Use and the Risk of Parkinson’s Disease
Manthripragada, A. D., Schernhammer, E. S., Qiu, J., Friis, S., Wermuth, L., Olsen, J. H., & Ritz, B. R. (2011) · Neuroepidemiology · doi:10.1159/000325653 · Cited by 57
Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease
Yonova-Doing, E., Atadzhanov, M., Quadri, M., Kelly, P., Shawa, N., Musonda, S. T. S., Simons, E. J., Breedveld, G. J., Oostra, B. A., & Bonifati, V. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.02.018 · Cited by 56
Biologic TNFα-inhibitors that cross the human blood-brain barrier
Pardridge, W. M. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.4.12105 · Cited by 53
Song, I., Chung, S., Kim, J., & Lee, K.-S. (2010) · Neurological Sciences · doi:10.1007/s10072-010-0335-0 · Cited by 52
Palasik, W., Fiszer, U., Lechowicz, W., Czartoryska, B., Krzesiewicz, M., & Ługowska, A. (2005) · European Neurology · doi:10.1159/000086355 · Cited by 52
Lin, Z., Chen, C., Yang, D., Ding, J., Wang, G., & Ren, H. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04002-1 · Cited by 49 · cited 2×
“DJ-1 knockout mice exhibit profound microglial activation compared with wild-type littermate controls, especially in response to LPS treatment [142].”
BackgroundSelf-citationSong, I., Kim, J., Chung, S., & Lee, K.-S. (2009) · European Neurology · doi:10.1159/000222780 · Cited by 49
Correlation between Protective Immunity to α-Synuclein Aggregates, Oxidative Stress and Inflammation
Алексеевна, Г. М., Yanamandra, K., Kucheryanu, V. G., Bocharova, O. R., Sherstnev, V. V., Morozova‐Roche, L. A., & Sewell, R. D. E. (2012) · NeuroImmunoModulation · doi:10.1159/000341400 · Cited by 44
Poletaev, A. B., Morozov, S., Gnedenko, B. B., Zlunikin, V. M., & Korzhenevskey, D. A. (2000) · Autoimmunity · doi:10.3109/08916930008995985 · Cited by 44
Impaired Production of Plasma Interleukin-6 in Patients with Parkinson's Disease
Selikhova, M. V., Кушлинский, Н. Е., Lyubimova, N. V., & Gusev, E. I. (2002) · Bulletin of Experimental Biology and Medicine · doi:10.1023/a:1015120930920 · Cited by 39
Is Neuroinflammation Involved in the Development of Dementia in Patients with Parkinson's Disease?
Song, I., Kim, Y., Cho, H.-J., & Chung, S. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.0474 · Cited by 38
Gangemi, S., Basile, G., Merendino, R. A., Epifanio, A., Pasquale, G. D., Ferlazzo, B., Nicita-Mauro, V., & Morgante, L. (2003) · Mediators of Inflammation · doi:10.1080/09629350310001599701 · Cited by 37
Maclagan, L. C., Visanji, N. P., Cheng, Y., Tadrous, M., Lacoste, A. M. B., Kalia, L. V., Bronskill, S. E., & Marras, C. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5015 · Cited by 37
DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys
Bélanger, N., Grégoire, L., Bédard, P. J., & Paolo, T. D. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.028 · Cited by 34
DJ-1 mutation decreases astroglial release of inflammatory mediators
Ashley, A. K., Hinds, A., Hanneman, W. H., Tjalkens, R. B., & Legare, M. E. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2015.12.007 · Cited by 32
An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes
Mahlknecht, P., Stemberger, S., Sprenger, F., Rainer, J., Hametner, E., Kirchmair, R., Grabmer, C., Scherfler, C., Wenning, G. K., Seppi, K., et al. (2012) · Proteome Science · doi:10.1186/1477-5956-10-71 · Cited by 31
Brandes, M. S., Zweig, J. A., Tang, A. L., & Gray, N. E. (2021) · Antioxidants · doi:10.3390/antiox11010026 · Cited by 30
Synucleinphagy: a microglial “community cleanup program” for neuroprotection
Choi, I., Seegobin, S. P., Liang, D., & Yue, Z. (2020) · Autophagy · doi:10.1080/15548627.2020.1774149 · Cited by 26
Dwyer, Z., Rudyk, C., Situt, D., Beauchamp, S., Abdali, J., Dinesh, A., Legancher, N., Sun, H., Schlossmacher, M. G., & Hayley, S. P. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100079 · Cited by 25
Neurodegenerative Disease: Autoimmunity Involving Calcium Channelsa
Appel, S. H., Smith, R., Alexianu, M. E., ENGELHARDT, J., Mosier, D., Colom, L. V., & Stefani, E. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb44409.x · Cited by 16
Neuroactive steroids and Parkinson's disease
Bourque, M., & Paolo, T. D. (2021) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2021.100312 · Cited by 11
Correlation between FEPPA uptake and microglia activation in 6-OHDA injured rat brain
Hatano, K., Yamada, T., Toyama, H., Kudo, G., Nomura, M., Suzuki, H., Ichise, M., Wilson, A. A., Sawada, M., Kato, T., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.04.112 · Cited by 7
Cited by
Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · doi:10.20944/preprints202506.2099.v2 · Cited by 57
Liu, J., Chen, Q., & Su, R. (2024) · Medicine · doi:10.1097/md.0000000000037960 · Cited by 25
Metadata
- Authors
- Liu, T.-W., Chen, C.-M., & Chang, K.-H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-04-08
- Volume
- 23
- Issue
- 8
- Pages
- 4148
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4224251003
- Cited by
- 259
- References
- 176
- FWCI
- 23.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.